Bristol-myers Squibb

This study tests a new drug called KarXT for schizophrenia in 250 Japanese adults experiencing acute psychosis. The trial has two parts: a 5-week period where some get the drug and some get a placebo, followed by a 52-week period where everyone gets the drug. The goal is to see i…

This study looks at how well the drug mavacamten works for Chinese adults with a heart condition called obstructive hypertrophic cardiomyopathy. About 500 people will be followed in regular clinics to see if the drug improves heart function and symptoms. The goal is to understand…

This study compares a new drug called pumitamig to the standard treatment pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer whose tumors have high levels of a protein called PD-L1. The goal is to see if pumitamig works better at stopping cancer growth a…

This study tests whether a new drug called pumitamig works better than the current standard drug durvalumab for people with stage III lung cancer that cannot be removed by surgery. Participants must have finished chemotherapy and radiation without their cancer getting worse. The …

This early-stage study tests a new drug called BMS-986500 in people with advanced solid tumors or breast cancer that has stopped responding to standard treatments. The main goal is to check safety and find the right dose. About 234 adults will take part, receiving the drug alone …

This study compares a new drug called pumitamig combined with chemotherapy against the standard treatment (nivolumab plus chemotherapy) for people with advanced or metastatic stomach, gastroesophageal junction, or esophageal cancer that hasn't been treated yet. About 690 particip…

This early-stage study tests an experimental drug called BMS-986504 in 32 Japanese and Chinese adults with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check the drug's safety and how the body processes it. Participants must hav…

This study tests a new drug, BMS-986504, in people with advanced or spreading non-small cell lung cancer that has a specific genetic change (MTAP deletion) and has stopped responding to other treatments. The goal is to see if the drug can shrink tumors or control the disease. Abo…

This study provides ongoing treatment with deucravacitinib for people with lupus (SLE or DLE/SCLE) who finished a previous study. It aims to keep managing the disease long-term. Only 35 participants who are likely to benefit and meet eligibility criteria will be enrolled.

This study follows 200 Italian adults with moderate to severe psoriasis who are already taking deucravacitinib. Researchers will track how well the drug controls symptoms, its side effects, and how it affects quality of life over time. The goal is to see how the treatment works i…

This study tests an oral medication called deucravacitinib in teenagers aged 12 to 17 with moderate to severe plaque psoriasis. The goal is to see if the drug safely improves skin clearance and reduces itching compared to a placebo. About 366 participants will take the pill daily…

This study tests whether a new drug called pumitamig, when added to chemotherapy, works better than the current standard treatment (bevacizumab plus chemo) for people with advanced colorectal cancer that cannot be removed by surgery. About 990 adults who have not had prior treatm…

This study tests a drug called luspatercept in adults and adolescents with alpha-thalassemia, a genetic blood condition that causes anemia. The goal is to see if the drug can reduce the need for blood transfusions or increase hemoglobin levels. Participants will receive either lu…

This program offers expanded access to iberdomide for people who may benefit from it but cannot join a clinical trial. It is designed for eligible participants with serious conditions who have no other treatment options. The goal is to provide early access to this investigational…

This study tests a new drug called KarXT for people with Bipolar I disorder who are currently having a manic episode (feeling extremely high energy, irritable, or agitated). About 274 adults who need hospital care for mania will receive either KarXT or a placebo for several weeks…

This study tests an oral medication called ozanimod in 120 children aged 12-17 with moderate-to-severe ulcerative colitis who haven't improved with standard treatments. The goal is to see if the drug can safely bring the disease into remission (no symptoms) and keep it there. Par…

This study tests whether a new experimental drug called BMS-986489, when combined with standard chemotherapy, works better than the current standard treatment (atezolizumab plus chemo) for people with extensive-stage small cell lung cancer. The trial will enroll about 530 partici…

This study tests a new drug, BMS-986517, in adults with advanced solid tumors that have spread or cannot be removed. The main goal is to check safety and side effects, and also to see if the drug shrinks tumors. About 315 participants will take the drug alone, without other cance…

This early-stage trial tests an experimental drug, MRTX1719, in adults with advanced solid tumors that have a specific genetic change (loss of the MTAP gene). The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants wit…

This early-stage study tests a new medicine called BMS-986470 in healthy volunteers and people with sickle cell disease. The main goal is to check safety and how the body handles the drug. Up to 184 participants will receive either the drug or a placebo to find the right dose and…

This study tests a new drug, BMS-986340, alone or with other cancer treatments in people with advanced solid tumors that have not responded to standard therapy. The main goal is to find safe doses and check for side effects. About 949 adults with various cancers like lung, breast…

This study tests an oral medication called deucravacitinib in 60 children aged 5 to 17 with active juvenile psoriatic arthritis. The goal is to see if the drug can control the disease and prevent flare-ups. Participants must have tried at least one other treatment without success…

This study tests a new drug called BMS-986525, given alone or with another drug (nivolumab), in people whose small cell lung cancer has come back or stopped responding to treatment. The main goals are to check safety and find the right dose. About 240 adults who have already had …

This study tests a new drug called pumitamig, alone or with other medicines (ipilimumab or cabozantinib), in people with advanced kidney cancer that has spread. The goal is to see if these combinations are safe and can shrink tumors or slow the disease. About 234 adults with clea…

This early-phase study tests an experimental drug called BMS-986460 in men with metastatic castration-resistant prostate cancer, a type of prostate cancer that has spread and stopped responding to standard hormone treatments. The main goals are to check the drug's safety and find…

This study is testing a new drug, CC-92480, combined with other therapies for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to find safe doses and see if the combination can shrink tumors. About 260 participants will take part in this…

This study tests whether adding an experimental drug (BMS-986504) to standard immunotherapy (pembrolizumab) and chemotherapy helps people with a specific type of advanced lung cancer live longer without their disease getting worse. About 590 adults with metastatic non-small cell …

This study tests an experimental drug called BMS-986435 in people with a type of heart failure where the heart pumps normally but is too stiff to fill properly (HFpEF). The goal is to see if the drug is safe and how the body processes it. About 208 adults with stable symptoms wil…

This study tests a new drug called pumitamig, either alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. About 129 participants will receive the treatment to see if it is safe and helps shrink tumors. The goal is to con…

This study tests a new experimental drug, BMS-986458, in people with non-Hodgkin lymphoma that has returned or not responded to prior therapies. The drug works by breaking down a protein inside cancer cells that helps them grow. Researchers will test it alone and with other lymph…

This program offers expanded access to mezigdomide, an experimental drug, for people with serious conditions who cannot join a clinical trial. It is designed to provide treatment when no other options are available. Participants must meet specific eligibility criteria set by the …

This study tests whether a new drug, iberdomide, works better than the current standard lenalidomide as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. About 1,200 participants will receive either drug to see which one delays canc…

This study looks at how well ozanimod works compared to azathioprine for people with steroid-dependent ulcerative colitis in Japan. Researchers will track 150 adults to see if they can achieve remission without needing steroids. The goal is to find a safer, more effective long-te…

This study tests a new drug, izalontamab brengitecan, against standard chemotherapy for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that has gotten worse after taking targeted pills called EGFR tyrosine kinase inhibitors. About 596 adults …

This study looks at the long-term safety of a drug called KarXT for people with Bipolar-I disorder who have mania or mixed episodes. About 450 adults who either completed a previous study or are new participants will take KarXT and be monitored for side effects. The goal is to se…

This study looks at how the drug KarXT affects bladder function and overall safety in 60 adults with schizophrenia over 12 months. Participants must stop their current antipsychotic medications before starting. The goal is to understand any urinary side effects and ensure the dru…

This study tests two different dosing schedules of a subcutaneous (under-the-skin) form of the immunotherapy drug nivolumab, given together with intravenous ipilimumab and chemotherapy. The goal is to find the best dosing regimen for people with previously untreated metastatic or…

This study monitors 200 people in Japan who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and blocks blood flow. Researchers will track side effects and how well the drug works in everyday medical practice. The …

This study tests whether adding a new targeted drug (BMS-986504) to standard chemotherapy can help people with a specific type of advanced pancreatic cancer live longer without their disease getting worse. The trial is for people whose tumors have a missing MTAP gene, which may m…

This study tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy in about 500 people with advanced triple-negative or ER-low breast cancer who cannot receive immunotherapy. The drug is designed to target and kill cancer cells while sparing hea…

This phase 3 trial compares two immunotherapy combinations for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of 1% or higher. Participants receive either nivolumab plus relatlimab with chemotherapy or pembrolizumab with chemotherapy. The study aims …

This early-stage study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The main goals are to check safety and find the right dose. About 360 adults with certain cancers (like colorectal or …

This study tests an experimental drug called BMS-986523, either alone or with other cancer medicines, in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have a specific genetic change (KRAS). The main goals are to see if the drug is safe and to fin…

This study compares two daily pills, ozanimod and fingolimod, in children and adolescents aged 10 to 17 with relapsing-remitting multiple sclerosis (RRMS). The goal is to see which drug better prevents relapses and controls brain lesions seen on MRI. Participants will be randomly…

This study tests the long-term safety of two oral drugs—deucravacitinib and ustekinumab—in about 3,040 adults with moderate-to-severe plaque psoriasis who also have at least one heart risk factor (like smoking, high blood pressure, or diabetes). Participants will be randomly assi…

This early-stage study tests a new drug, BMS-986497, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The drug is given alone or with standard medicines (azacitidine and venetoclax) to find the safest…

This study tests a new drug called izalontamab brengitecan against standard chemotherapy for people with advanced bladder cancer that got worse after immunotherapy. About 470 adults will be randomly assigned to receive either the new drug or chemo. The goal is to see if the new d…

This study looks at how well a drug called mavacamten works for adults in Japan who have a heart condition called obstructive hypertrophic cardiomyopathy (HOCM). In HOCM, the heart muscle is too thick and blocks blood flow, causing symptoms like chest pain and shortness of breath…

This early-phase study tests a new drug called BMS-986463 in people with advanced ovarian, uterine, or lung cancer that has spread or cannot be removed by surgery. The main goals are to check the drug's safety and find the best dose. About 240 participants will receive increasing…

This early-stage study tests a new drug called BMS-986506 in people with advanced clear cell kidney cancer that has not responded to prior treatments. The main goal is to check the drug's safety and find the right dose. About 125 participants will take the drug alone to see if it…

This study tests an experimental drug called BMS-986482, given alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 413 adults will take part. The stu…

This study is testing a new medicine called BMS-986326 in 44 adults with discoid, subacute cutaneous, or systemic lupus. The main goal is to see if the drug is safe and how it behaves in the body after multiple doses given by IV or injection. Participants will be randomly assigne…

This study is testing a drug called luspatercept in adults with a severe blood disorder called beta-thalassemia who need regular blood transfusions. The goal is to see if the drug can reduce how many transfusions they need and improve their hemoglobin levels. About 200 people in …

This study tests a new drug combination (BMS-986507) in about 416 adults with advanced solid tumors, specifically lung and breast cancers. The goal is to find safe doses and see if the treatment can shrink tumors. Participants must have measurable tumors and be in fairly good hea…

This study is tracking 1500 adults with schizophrenia who are starting a new medication called KarXT (xanomeline and trospium chloride). Researchers want to see how well it works and what side effects occur in everyday medical practice, not just in a controlled lab. The goal is t…

This study tests a drug called KarXT in 166 teenagers (13-17 years old) with schizophrenia. The goal is to see if KarXT safely reduces symptoms like hallucinations and confusion compared to a placebo. Participants will take the drug or a dummy pill for several weeks, and doctors …

This study looks at whether switching teen kidney transplant patients (ages 12-17) from standard anti-rejection drugs to a newer medication called belatacept can help preserve kidney function and improve how consistently they take their medicine. About 102 participants will be ra…

This study is for cancer patients who have already taken part in earlier trials of nivolumab or other BMS cancer treatments. The main goal is to check the long-term safety of continuing these therapies. About 1,500 participants with various tumor types will be enrolled. The study…

This study tests an oral drug called deucravacitinib in children aged 4 to 18 with moderate to severe plaque psoriasis. The goal is to see if it safely reduces skin symptoms and improves quality of life. About 153 participants will receive either the drug or a placebo, and those …

This study tests whether a new combination drug, KarXT + KarX-EC, can safely reduce hallucinations and delusions in people with Alzheimer's disease. About 325 adults aged 55 to 90 with Alzheimer's and psychosis will receive either the drug or a placebo. The goal is to see if the …

This study tests whether a combination of two drugs (KarXT and KarX-EC) can improve memory, thinking, and daily function in people with mild to moderate Alzheimer's disease. About 586 volunteers will receive either the drug combo or a placebo pill. The goal is to see if the treat…

This early-stage study is testing a long-acting injectable form of KarXT for people with schizophrenia. The main goals are to check safety and how the drug moves through the body. About 48 participants will receive a single injection, and researchers will monitor for side effects…

This study tests whether a combination of two drugs, KarXT and KarX-EC, can safely reduce agitation in people with Alzheimer's disease. About 352 adults with Alzheimer's-related agitation will receive either the study drug or a placebo. The main goal is to see if agitation scores…

This study tests whether the drug KarXT can reduce symptoms of mania in people with Bipolar I disorder who are currently hospitalized for an acute manic episode. About 274 participants will receive either KarXT or a placebo for 3 weeks while staying in the hospital. The goal is t…

This study tests whether adding the drug KarXT to standard mood stabilizers (lithium, valproate, or lamotrigine) can better control manic episodes in people with Bipolar I disorder. About 424 adults hospitalized for mania will receive either KarXT or a placebo for 5 weeks. The ma…

This study tests whether a combination of two drugs, KarXT and KarX-EC, can safely reduce agitation in people with Alzheimer's disease. About 352 adults with Alzheimer's-related agitation will receive either the drug combination or a placebo. The main goal is to see if agitation …

This study is for people with Alzheimer's disease who experience agitation and have already completed a related study. It tests the long-term safety of a drug called KarXT, which combines two medications to help calm agitation. About 600 participants will take the drug and be mon…

This study tests whether a new drug combination, KarXT + KarX-EC, can improve memory and thinking in people with mild to moderate Alzheimer's disease. About 586 participants will receive either the drug or a placebo, and researchers will measure changes in thinking skills and dai…

This early-stage study tests the safety and how the body handles an experimental drug called BMS-986521. About 106 healthy adults will receive either the drug or a placebo. The goal is to check for side effects and measure drug levels in the blood, not to treat any disease.

This study is tracking 362 adults with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow) who are taking the drug mavacamten in regular U.S. clinics. Researchers want to see how the drug affects blood pressure, heart functi…

This study is a registry that will follow about 1,600 people in the US and Europe with a type of heart disease called obstructive hypertrophic cardiomyopathy. Researchers will observe how patients are treated in real-world settings, including those taking the drug mavacamten or o…

This study follows pregnant women with multiple sclerosis who have taken ZEPOSIA to see how it affects their pregnancy and their baby's health. Researchers will collect information on birth defects, pregnancy complications, and infant development. The goal is to help patients and…

This study interviews 55 people — patients with early-stage non-small cell lung cancer and their doctors — to learn what they value most in treatment options. It does not test a new drug or procedure, but aims to gather insights to improve future care decisions. Participants are …

This study aims to understand the quality of life, symptoms, and unmet needs of 50 people in Japan with low-risk myelodysplastic syndrome (MDS) or unexplained anemia. Participants will fill out questionnaires and some will have interviews about their experiences. No new treatment…

This study is observing 300 adults with schizophrenia in the U.S. who are prescribed a new medication called KarXT (xanomeline and trospium chloride). Researchers want to learn how satisfied patients are with the treatment and whether they prefer it over other options. No new tre…

This study looks at why some elderly Italian patients with a common heart rhythm problem (non-valvular atrial fibrillation) start taking blood thinners and others do not. Researchers will follow 720 patients for one year to see how many stick with their treatment and how many swi…

This study monitors the safety of the heart medication mavacamten when taken during pregnancy or while breastfeeding. Researchers will track outcomes for mothers, fetuses, and infants up to one year after birth. The goal is to better understand any risks, not to test a new treatm…

This study looks at tumor samples from 50 people who received a Bristol-Myers Squibb gene-modified cell therapy for blood cancers like lymphoma or myeloma and later developed a second cancer. Researchers will test these samples to see if any therapy-related genes are present. The…

This study looks at how well different tablet versions of the drug BMS-986435 are absorbed by the body in healthy adults. It also checks if eating food changes how the drug is absorbed. The study involves 140 healthy volunteers and aims to gather important information for future …

This early study looks at how the experimental drug BMS-986504 is absorbed, broken down, and removed from the body in people with advanced solid tumors that lack a specific gene (MTAP). Only 8 participants will take a single dose, and researchers will measure drug levels in blood…

This early-stage study is testing new versions of experimental drugs called KarX and KarT in 72 healthy adults. The goal is to see how the body absorbs and processes these prototypes compared to the original drug, and whether food changes their effects. Participants will receive …

This study tests whether the experimental drug BMS-986278 changes the heart's electrical activity in 32 healthy adults aged 18 to 55. Participants receive the drug, a placebo, and a positive control in random order. The goal is to check for heart rhythm risks, not to treat any di…

This study is observing 223 people with active lupus (including kidney inflammation) who have not improved with steroids and at least two immunosuppressants. Researchers will track how many achieve remission or low disease activity after 6 months of standard care. The goal is to …